文献速递其他结缔组织病

特发性炎性肌病血清半乳糖凝集素-3水平:疾病活动性的潜在生物标志物

Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该研究评估特发性炎性肌病(IIM)患者血清和组织中半乳糖凝集素-3的表达及其与疾病活动的关联。结果显示IIM患者血清半乳糖凝集素-3显著高于健康对照,且与炎症标志物、促炎细胞因子/趋化因子及肌炎活动指数正相关,在IIM相关间质性肺病(IIM-ILD)患者中更高,并与肺实质受累影像评估及治疗反应相关。

要点

  • IIM患者血清半乳糖凝集素-3显著高于健康对照。
  • 血清半乳糖凝集素-3与炎症标志物及肌炎活动指数正相关。
  • IIM-ILD患者血清半乳糖凝集素-3更高,且与肺受累及治疗反应相关。

核心结论

  • 半乳糖凝集素-3可能参与IIM炎症和纤维化病理过程,可作为疾病活动性的潜在生物标志物,尤其用于IIM-ILD患者。

研究设计与样本

  • 研究评估了IIM患者血清和组织中半乳糖凝集素-3的表达,并分析其与患者特征及疾病活动的关联。

主要发现

  • IIM患者血清半乳糖凝集素-3水平显著高于健康对照。
  • 血清半乳糖凝集素-3与血清炎症标志物、促炎细胞因子/趋化因子水平及肌炎意向治疗活动指数正相关。
  • IIM-ILD患者血清半乳糖凝集素-3显著高于无IIM-ILD者,急性/亚急性间质性肺炎患者显著高于慢性间质性肺炎患者。
  • IIM-ILD患者血清半乳糖凝集素-3与肺实质受累影像评估及治疗反应相关。
  • 免疫组化显示半乳糖凝集素-3表达于肌炎和皮炎切片炎症细胞,ILD切片中间质纤维化和炎症细胞亦表达。

临床怎么用

  • 血清半乳糖凝集素-3可作为评估IIM疾病活动性尤其是IIM-ILD的潜在生物标志物,辅助识别肺受累及治疗反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Galectin-3 is involved in various biological activities, including immune activations and fibrosis. Idiopathic inflammatory myopathies (IIMs) are autoimmune diseases of unknown aetiology, often complicated by interstitial lung disease (ILD). The aim of this study was to evaluate the expression of galectin-3 in sera and tissues of patients with IIM and assess the associations of galectin-3 with patient characteristics and disease activity. RESULTS: Serum galectin-3 levels were significantly higher in IIM patients than in healthy controls. The serum galectin-3 levels positively correlated with serum levels of inflammatory markers and proinflammatory cytokines/chemokines and the Myositis Intention-to-Treat Activity Index. Stratification analysis revealed that patients with IIM-associated ILD (IIM-ILD) had significantly higher levels of serum galectin-3 than those without IIM-ILD. In addition, patients with acute/subacute interstitial pneumonia had significantly higher levels of serum galectin-3 than those with chronic interstitial pneumonia. Furthermore, serum galectin-3 levels in IIM-ILD patients correlated with the radiological assessments of parenchymal lung involvement and treatment response. Immunohistochemical analysis revealed that galectin-3 was expressed in inflammatory cells of myositis and dermatitis sections, whereas in ILD sections, galectin-3 was expressed in interstitial fibrosis and inflammatory cells. CONCLUSION: Galectin-3 may be involved in the pathogenesis of inflammatory and fibrotic conditions in IIM and can serve as a potential biomarker of disease activity, especially in patients with IIM-ILD.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Watanabe E, Kato K, Gono T, et al. Serum levels of galectin-3 in idiopathic inflammatory myopathies: a potential biomarker of disease activity. Rheumatology (Oxford). 2021. PMID: 32770187. doi:10.1093/rheumatology/keaa305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。